literature

HBV mutation literature information.

Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.

PMID: 31189581 2019 Journal of clinical microbiology

Introduction: For instance, I195M in the S protein (sI195M) and sW196S can produce rtM204I and rtL180M/rtM204I in RT, which could confer resistance to LMV.

Introduction: For instance, M204V/I in RT (rtM204V/I) is a classical lamivudine (LMV) resistance mutation, which also greatly reduces susceptibility to telbivudine (LdT); rt

Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naive chronically infected patients.

PMID: 31179360 2019 Virusdisease

Abstract: Drug resistance conferring substitutions (DRCSs) were rtL180M (22/98), rtA194V (11/98), rtM204V (1/98), and rtM204I (11/98).

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.

PMID: 31147594 2019 Scientific reports

Introduction: These two categories are known as classical mutations, which include: (i) M204I/V mutation, which associates with LAM or LDT resistance; (ii) N236T or A181T/V mutations, which associate with ADV resistance; (iii) M204V + L180M and either T184A/G/I/L/S or S202G or M250V to develop resistance to ETV.

Discussion: reported that an combined mutation pattern of L80M, L180M, M204V/I, A200V, F221Y, S223A, T184A/L,

[HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].

PMID: 31130119 2019 Mikrobiyoloji bulteni

Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.

PMID: 30906435 2019 Experimental and therapeutic medicine

Result: Common and frequent mutations identified in the cohort of the present study included rtL80V/I, rtV84M, rtL91I, rtN118H/D/T, rtT128A, rtL180M, rtT184L/S/A, rtV191I, rtS202G, rtV207I/M, rtS213T

Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan.

PMID: 30867996 2019 PeerJ

Discussion: M204I/V

Discussion: A recent meta-analysis has shown that the incidence of spontaneous primary and secondary mutations among untreated chronic hepatitis B patients was 4.9% for primary mutations of rtM204V/I, while the natural incidence of secondary rtL180M mutations was 2.7%.

Discussion: For example, dual rtL180M and M204V/I mutants were frequently found in patients in Italy, with three patients having triple mutation of rtV173L, rtL180M and M204V.

Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.

PMID: 30866789 2019 Emerging microbes & infections

Abstract: Artificial elimination of rtA181C largely restored the rtL180M+A181C+M204V mutant's sensitivity to ETV.

Result: Additional introduction of rtS202G or rtM250V into rtL180M+A181C+M204V mutation pattern resulted in one N-H:O bond reduction with further increased binding energy (Table 4).

Result: Afterwards, therapy was switched to an ADV+ETV Clonal sequencing of serum samples E3 and E4 during the combination therapy showed that the rt

Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients.

PMID: 30796932 2019 Antiviral research

Abstract: Classical ETV-resistance mutations rtT184/S202/M250substitution+rtM204V/I+-L180M (LAM-r), rtA186T, and rtI163V were detected in 1252 (5.69%), 14 (0.06%), and 230 (1.05%) of the 22,009 patients, respectively.

Abstract: Compared to wild-type strain, two patient-derived mutants' rtL180M+A186T+M204V and rtL180M+T184S+A186T+M204V had 86.7% and 89.2% decreased replication capacity, 210

CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

PMID: 30670420 2019 Antimicrobial agents and chemotherapy

Abstract: CMCdG also reduced the level of HBVETV-R L180M/S202G/M204V viremia by ~1 log in HBVETV-R L180M/S202G/M204V-infected human liver-chimeric mice, while ETV (1 mg/kg/day q.d.) completely failed to reduce the viremia.

Abstract: CMCdG potently inhibited HBV production in HepG2.2.15 cells (50% inhibitory concentration [IC50], ~30 nM) and HBVWT Ce plasmid-transfected Huh7 cells (IC50, 206 nM) and efficiently suppressed ETV-resistant HBVETV-R L180M/S202G/M204V (IC50, 2,657 nM), while it showed no or little cytotoxicity (50% cytotoxic concentration, >500 muM in most hepatocytic cells examined).

Abstract: CMCdG's in vitro activity was determined using quantitative PCR a

Synthesis of an Anti-hepatitis B Agent, 2'-Fluoro-6'-methylene-carbocyclic Adenosine (FMCA) and Its Phosphoramidate (FMCAP).

PMID: 30589264 2019 The Journal of organic chemistry

Abstract: 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 12) and its phosphoramidate prodrug (FMCAP, 14) have been proven as a potential anti-HBV agent against both adefovir-resistant as well as lamivudine-resistant double (rtL180M/rtM204V) mutants.

Abstract: Furthermore, in vitro, these agents have demonstrated significant activity against lamivudine/entecavir triple mutants (L180M + S202G + M204V).

Browser Board

Co-occurred Entities

Filtrator